Visualitzant O - Articles científics per títol

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

Kramer, Claire; Yaniz-Galende, Elisa; Pellegrino, Benedetta; ter Haar, Natalja; Llop-Guevara, Alba; Herencia Ropero, Andrea; Serra, Violeta (Wiley, 2023-11)

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Compadre, Amanda; van Biljon, Lillian; Valentine, Mark; Graham, Emily; Fashemi, Bisiayo; Herencia Ropero, Andrea; Llop-Guevara, Alba; Serra, Violeta (American Association for Cancer Research, 2023-07-01)

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

Ramlee, Syafiq; Hulse, David; Bernatowicz, Kinga; Pérez López, Raquel; Sala, Evis; Aloj, Luigi (MDPI, 2022-07-27)

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

Carles Galceran, Joan; Mellado, Begoña; Méndez-Vidal, María J.; Vázquez, Sergio; Gonzalez-del-Alba, Aranzazu; Morales Barrera, Rafael; Alonso-Gordoa, Teresa (Elsevier, 2022-09)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Heidenreich, Axel; Gillessen, Silke; Heinrich, Daniel; Keizman, Daniel; O'Sullivan, Joe M; Carles Galceran, Joan (BMC, 2019-01-07)

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Besse, Benjamin; Garcia Campelo, Rosario; cobo, manuel; Mascaux, C; Madroszyk, Anne; FELIP, ENRIQUETA (Elsevier, 2023-09-11)

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Aparicio, Jorge; Virgili Manrique, Anna Cristina; Muñoz Boza, Félix; Galván, Patricia; Richart, Paula; Hernando Cubero, Jorge; Capdevila Castillon, Jaume (Springer, 2022-11)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

Choueiri, T.; Suárez Rodríguez, Cristina; Hainsworth, John; Voog, Eric; Duran, Ignacio; Porta, Camillo (Oxford University Press, 2022-12)

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Van Cutsem, Eric; Tempero, Margaret A.; Sigal, Darren; Fazio, Nicola; Macarulla Mercadé, Teresa; Oh, Do-Youn (American Society of Clinical Oncology, 2020-09-20)

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

Antolin Novoa, Silvia; Tolosa, Pablo; Oliva Fernández, Lucía; López López, Rafael; López González, Ana; Escriva de Romani, Santiago (Elsevier, 2023)

Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)

Bergas, Alba; Albasanz Puig, Adaia; Fernández-Cruz, Ana; Machado, Marina; Novo, Andrés; van Duin, David; Ruiz- Camps, Isabel; Aguilar-Company, Juan (American Society for Microbiology, 2022-06)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Pascual, Cristina; Mingot Castellano, María Eva; Kerguelen Fuentes, Ana Esther; García-Arroba Peinado, José; Cid, Joan; Jiménez, Moraima; VALCARCEL, DAVID (American Society of Hematology, 2022-12-27)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

IACOBONI, GLORIA; Rejeski, Kai; Villacampa Javierre, Guillermo; van Doesum, Jaap; CHIAPPELLA, ANNALISA; Bonifazi, Francesca; Camacho-Arteaga, Lina ; Marin Niebla, Ana; Barba, Pere (American Society of Hematology, 2022-06-28)

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

Iacoboni García-Calvo, Gloria; Martinez-Cibrian, Nuria; Bailén, Rebeca; Corral, Lucia Lopez; Sanchez, Jose M.; Abrisqueta Costa, Pablo; Barba Suñol, Pere; Villacampa Javierre, Guillermo (Wiley, 2021-05)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

Dieras, Veronique; Cortés Castan, Javier; Patt, Debra; Wildiers, Hans; O’Shaughnessy, Joyce; Zamora Adelantado, Esther; Rugo, Hope (Springer, 2020-11)

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

Popat, Sanjay; Brustugun, Odd Terje; Cadranel, Jacques; Felip Font, Enriqueta; Garassino, Marina Chiara; Griesinger, Frank (Elsevier, 2021-07)

Recent advances in the targeting of epigenetic regulators in b-cell non- Hodgkin lymphoma

Ribeiro Lima, Marcelo; Reyes Garau, Diana; Armengol, Marc; Fernández Serrano, Miranda; Roue, Gael (Frontiers Media, 2019-10-16)

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

Vitiello, Pietro Paolo; Martini, Giulia; Ciardiello, Davide; Belli, Valentina; Matrone, Nunzia; Cardone, Claudia (BMC, 2019-01-28)

Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients

Vera, Ruth; Otero, M. J.; Ayala de la Peña, Francisco; González-Pérez, C.; Peñuelas Saiz, Angeles; Sepúlveda, Juan Manuel; Gorgas Torner, Maria Queralt (Springer, 2019-04)

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

Canaro Hirnyk, Mariana ; Sánchez-González, Blanca; Álvarez Román, María Teresa; Bárez-García, Abelardo; Bernardo, Angel; Mingot Castellano, María Eva; VALCARCEL, DAVID (MDPI, 2023-10-10)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

Recent advances in the targeting of epigenetic regulators in b-cell non- Hodgkin lymphoma

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test ﻿

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer ﻿

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study ﻿

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial ﻿

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program ﻿

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1 ﻿

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01) ﻿

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy ﻿

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma ﻿

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study) ﻿

Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study) ﻿

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura ﻿

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma ﻿

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma ﻿

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1 ﻿

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer ﻿

Recent advances in the targeting of epigenetic regulators in b-cell non- Hodgkin lymphoma ﻿

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines ﻿

Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients ﻿

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI) ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

Recent advances in the targeting of epigenetic regulators in b-cell non- Hodgkin lymphoma

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)